Myeloablative busulfan/melphalan (BuMel) consolidation following induction chemotherapy for patients with high-risk neuroblastoma: A Children’s Oncology Group (COG) study.

Meaghan Granger; Gregory A. Yanik; Arlene Naranjo; Jeannine S. McCune; Steven G. DuBois; Rochelle Bagatell; Brian D. Weiss; Stephan A. Grupp; Sheena Cretella Tenney; Shahab Asgharzadeh; Michael D. Hogarty; Joseph Ezra Panoff; John Han-Chih Chang; Julie M Gastier-Foster; Denise Mills; Julie R. Park

doi:10.1200/jco.2016.34.15_suppl.10528

Myeloablative busulfan/melphalan (BuMel) consolidation following induction chemotherapy for patients with high-risk neuroblastoma: A Children’s Oncology Group (COG) study.

Meaghan Granger, Gregory A. Yanik, Arlene Naranjo, Jeannine S. McCune, Steven G. DuBois, Rochelle Bagatell, Brian D. Weiss, Stephan A. Grupp, Sheena Cretella Tenney, Shahab Asgharzadeh, Michael D. Hogarty, Joseph Ezra Panoff, John Han-Chih Chang, Julie M Gastier-Foster, Denise Mills, Julie R. Park

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Clinical Oncology
Volume	34
DOIs	https://doi.org/10.1200/jco.2016.34.15_suppl.10528
State	Published - May 20 2016

Disciplines

Physical Therapy
Medicine and Health Sciences
Critical Care

Access to Document

10.1200/jco.2016.34.15_suppl.10528License: Unspecified

Cite this

Granger, M., Yanik, G. A., Naranjo, A., McCune, J. S., DuBois, S. G., Bagatell, R., Weiss, B. D., Grupp, S. A., Tenney, S. C., Asgharzadeh, S., Hogarty, M. D., Panoff, J. E., Chang, J. H.-C., Gastier-Foster, J. M., Mills, D., & Park, J. R. (2016). Myeloablative busulfan/melphalan (BuMel) consolidation following induction chemotherapy for patients with high-risk neuroblastoma: A Children’s Oncology Group (COG) study. Journal of Clinical Oncology, 34. https://doi.org/10.1200/jco.2016.34.15_suppl.10528

Granger, M, Yanik, GA, Naranjo, A, McCune, JS, DuBois, SG, Bagatell, R, Weiss, BD, Grupp, SA, Tenney, SC, Asgharzadeh, S, Hogarty, MD, Panoff, JE, Chang, JH-C, Gastier-Foster, JM, Mills, D & Park, JR 2016, 'Myeloablative busulfan/melphalan (BuMel) consolidation following induction chemotherapy for patients with high-risk neuroblastoma: A Children’s Oncology Group (COG) study.', Journal of Clinical Oncology, vol. 34. https://doi.org/10.1200/jco.2016.34.15_suppl.10528

@article{4648c2a4eb404a97a8bf3ff0c4b15800,

title = "Myeloablative busulfan/melphalan (BuMel) consolidation following induction chemotherapy for patients with high-risk neuroblastoma: A Children{\textquoteright}s Oncology Group (COG) study.",

author = "Meaghan Granger and Yanik, {Gregory A.} and Arlene Naranjo and McCune, {Jeannine S.} and DuBois, {Steven G.} and Rochelle Bagatell and Weiss, {Brian D.} and Grupp, {Stephan A.} and Tenney, {Sheena Cretella} and Shahab Asgharzadeh and Hogarty, {Michael D.} and Panoff, {Joseph Ezra} and Chang, {John Han-Chih} and Gastier-Foster, {Julie M} and Denise Mills and Park, {Julie R.}",

note = "Background: The COG conducted a groupwide study of a Busulfan/Melphalan (BuMel) myeloablative regimen in patients with newly diagnosed, high-risk neuroblastoma (ANBL12P1). Previously used in SIOP-EN studies, this is the first trial using BuMel following a COG induction platform. The primary objective was regimen-related toxicity, with a specific focus on pulmonary and hepatic events.",

year = "2016",

month = may,

day = "20",

doi = "10.1200/jco.2016.34.15_suppl.10528",

language = "American English",

volume = "34",

journal = "Journal of Clinical Oncology",

}

TY - JOUR

T1 - Myeloablative busulfan/melphalan (BuMel) consolidation following induction chemotherapy for patients with high-risk neuroblastoma: A Children’s Oncology Group (COG) study.

AU - Granger, Meaghan

AU - Yanik, Gregory A.

AU - Naranjo, Arlene

AU - McCune, Jeannine S.

AU - DuBois, Steven G.

AU - Bagatell, Rochelle

AU - Weiss, Brian D.

AU - Grupp, Stephan A.

AU - Tenney, Sheena Cretella

AU - Asgharzadeh, Shahab

AU - Hogarty, Michael D.

AU - Panoff, Joseph Ezra

AU - Chang, John Han-Chih

AU - Gastier-Foster, Julie M

AU - Mills, Denise

AU - Park, Julie R.

N1 - Background: The COG conducted a groupwide study of a Busulfan/Melphalan (BuMel) myeloablative regimen in patients with newly diagnosed, high-risk neuroblastoma (ANBL12P1). Previously used in SIOP-EN studies, this is the first trial using BuMel following a COG induction platform. The primary objective was regimen-related toxicity, with a specific focus on pulmonary and hepatic events.

PY - 2016/5/20

Y1 - 2016/5/20

UR - http://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.10528

U2 - 10.1200/jco.2016.34.15_suppl.10528

DO - 10.1200/jco.2016.34.15_suppl.10528

M3 - Article

VL - 34

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -

Myeloablative busulfan/melphalan (BuMel) consolidation following induction chemotherapy for patients with high-risk neuroblastoma: A Children’s Oncology Group (COG) study.

Disciplines

Access to Document

Other files and links

Cite this